NeOnc Receives FDA Written Feedback on NEO212 CMC Development and Capsule-to-Tablet Transition
Go back to NeOnc Receives FDA Written Feedback on NEO212 CMC Development and Capsule-to-Tablet Transition| (NASDAQ: NTHI) | Delayed: 3.67 +0.30 (8.90%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $3.37 | 52 Week High | $ | |||
| Open | $3.41 | 52 Week Low | $ | |||
| Day High | $3.85 | P/E | N/A | |||
| Day Low | $3.41 | EPS | $ | |||
| Volume | 89,318 | |||||
